Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
329 - 333
Mult Scler Relat Disord
MetadataShow full item record
The management of multiple sclerosis is becoming increasingly complex with the emergence of new and more effective disease-modifying therapies (DMT). We propose a new treatment paradigm that individualises treatment based on a choice between two interchangeable therapeutic strategies of maintenance-escalation or induction therapy. We propose treating- to-target of no evident disease activity (NEDA) as defined using clinical and MRI criteria. This algorithm requires active monitoring with a rebaselining MRI, at a point in time after the specific DMT concerned has had sufficient time to work, and at least annual MRI studies to monitor for subclinical relapses. Disease activity on the maintenance-escalation therapy arm of the algorithm indicates a sub-optimal treatment response and should trigger a discussion about switching, or escalating, therapy or the consideration of switching to the induction therapy arm of the algorithm. In comparison, disease activity on an induction therapy arm would be an indication for retreatment or a switch to the maintenance-escalation therapy arm. We envisage the definition of NEDA evolving with time as new technological innovations are adopted into clinical practice, for example the normalisation of whole, or regional, brain atrophy rates and cerebrospinal fluid neurofilament levels.
AuthorsGiovannoni, G; Turner, B; Gnanapavan, S; Offiah, C; Schmierer, K; Marta, M
- College Publications 
Showing items related by title, author, creator and subject.
Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis. Orlandi, M; Suvan, J; Petrie, A; Donos, N; Masi, S; Hingorani, A; Deanfield, J; D'Aiuto, F (2014-09)OBJECTIVE: This meta-analysis sought to investigate the association between carotid intima-media thickness (c-IMT), flow-mediated dilation (FMD) and periodontitis (PD) and to assess the effect of periodontal treatment on ...
Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bachanova, V; Burns, LJ; Wang, T; Carreras, J; Gale, RP; Wiernik, PH; Ballen, KK; Wirk, B; Munker, R; Rizzieri, DA;... (2015-02)Alternative donor transplantation is increasingly used for high-risk lymphoma patients. We analyzed 1593 transplant recipients (2000-2010) and compared transplant outcomes in recipients of 8/8 allele HLA-A, -B, -C and DRB1 ...
Lewis, A; Riddoch-Contreras, J; Natanek, SA; Donaldson, A; Man, WD; Moxham, J; Hopkinson, NS; Polkey, MI; Kemp, PR (2012-01)RATIONALE: Muscle atrophy confers a poor prognosis in patients with chronic obstructive pulmonary disease (COPD), yet the molecular pathways responsible are poorly characterised. Muscle-specific microRNAs and serum response ...